Azilsartan medoxomil/chlortalidone - Takeda

Drug Profile

Azilsartan medoxomil/chlortalidone - Takeda

Alternative Names: Chlortalidone/azilisartan medoxomil; EdarbiClo; Edarbyclor; TAK-491/chlorthalidone; TAK-491CLD

Latest Information Update: 14 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Takeda
  • Class Antihypertensives; Benzimidazoles; Small molecules; Sulfonamides
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Thiazide-like diuretics
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hypertension

Most Recent Events

  • 14 Sep 2017 Launched for Hypertension in Russia (PO) before September 2017 (Takeda Russia-CIS website, September 2017)
  • 14 Sep 2017 No recent reports on development identified - Registered for Hypertension in Brazil (PO)
  • 17 Aug 2017 Azilsartan medoxomil/chlorthalidone market licensed to Hikma Pharmaceuticals in Middle East and North Africa
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top